JPRN-UMIN000028474
Recruiting
N/A
An exploratory prospective study of the biomarkers of the immune-related adverse events (irAE) and the mechanisms of irAE in solid cancer patients treated with Pembrolizumab. - An exploratory study of immune-related adverse events in patients treated with Pembrolizumab.
Department of Internal Medicine, Division of Medical Oncology, Showa University School of Medicine.0 sites30 target enrollmentAugust 1, 2017
Conditionssolid cancer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- solid cancer
- Sponsor
- Department of Internal Medicine, Division of Medical Oncology, Showa University School of Medicine.
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) HBs antigen, HCV antibody and HIV antibody is positive. (2\) An inappropriate case judged by doctor in charge.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Prospective research of the biomarkers associated with adjuvant chemotherapy in patients with resectable biliary tract cancerBiliary tract cancerJPRN-UMIN000004613Department of Medical Oncology, University of Miyazaki Hospital50
Completed
N/A
The exploratory study to evaluate biomarkers in prospective multicenter observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer or extensive disease small cell lung cancer (J-TAIL-2)on-small cell lung cancer or extensive disease small cell lung cancerJPRN-UMIN000043663CHUGAI PHARMACEUTICAL CO., LTD.450
Completed
N/A
Exploratory study to investigate biomarkers associated with pathogenesis of infantile hemangioma.Infantile hemangiomaJPRN-UMIN000038574Wakayama Medical University45
Completed
N/A
An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancerliver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancerJPRN-UMIN000010429EPS Corporation100
Not Yet Recruiting
N/A
Exploratory research of biomarkers for investigational drugs using tear fluid samplesJPRN-UMIN000049186Santen Pharmaceutical Co. Ltd.29